AR124461A1 - VACUNA BASADA EN AAV5 PARA LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL SARS-CoV-2 Y/O LA PREVENCIÓN DE LA INFECCIÓN POR CORONAVIRUS RELACIONADA CON EL SARS-CoV-2 - Google Patents

VACUNA BASADA EN AAV5 PARA LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL SARS-CoV-2 Y/O LA PREVENCIÓN DE LA INFECCIÓN POR CORONAVIRUS RELACIONADA CON EL SARS-CoV-2

Info

Publication number
AR124461A1
AR124461A1 ARP210103609A ARP210103609A AR124461A1 AR 124461 A1 AR124461 A1 AR 124461A1 AR P210103609 A ARP210103609 A AR P210103609A AR P210103609 A ARP210103609 A AR P210103609A AR 124461 A1 AR124461 A1 AR 124461A1
Authority
AR
Argentina
Prior art keywords
cov
sars
induction
prevention
specific immunity
Prior art date
Application number
ARP210103609A
Other languages
English (en)
Inventor
Pavel Mikhailovich Gershovich
Alexander Vladimirovich Prokofyev
Anna Nikolaevna Strelkova
Natalia Aleksandrovna Spirina
Tatiana Evgenievna Shugaeva
Pavel Andreevich Iakovlev
Dmitry Valentinovich Morozov
Original Assignee
Joint Stock Company “Biocad”
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Joint Stock Company “Biocad” filed Critical Joint Stock Company “Biocad”
Publication of AR124461A1 publication Critical patent/AR124461A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente solicitud está relacionada con los campos de la biotecnología, la inmunología, la virología, la genética y la biología molecular. Más específicamente, la presente invención se refiere a un ácido nucleico aislado optimizado por codones que codifica un dominio recombinante aislado de unión al receptor de la glicoproteína S (RBD-S) del SARS-CoV-2 (coronavirus relacionado con el síndrome respiratorio agudo severo 2), a un casete de expresión y a un vector basado en el mismo, así como a un virus recombinante basado en el AAV5 (virus adeno-asociado de serotipo 5) para la inducción de la inmunidad específica al SARS-CoV2 y/o la prevención de la infección por el coronavirus relacionado con el SARS-CoV-2 a una vacuna basada en el AAV5 para la inducción de la inmunidad específica contra el SRAS-CoV-2 y/o la prevención de la infección por coronavirus relacionada con el SRAS-CoV-2, y a su uso para la inducción de la inmunidad específica contra el SRAS-CoV-2 y/o la prevención de la infección por coronavirus relacionada con el SRAS-CoV-2. Reivindicación 1: Un ácido nucleico aislado que codifica el dominio recombinante de unión al receptor de la glicoproteína S (RBD-S) del SARS-CoV-2 con la secuencia de aminoácidos de la SEQ ID Nº 1, que es la secuencia de nucleótidos de la SEQ ID Nº 18. Reivindicación 16: Una vacuna para la inducción de la inmunidad específica contra el SARS-CoV-2 y/o la prevención de la infección por coronavirus relacionada con el SARS-CoV-2, que incluye el virus recombinante basado en el AAV5 según cualquiera de las reivindicaciones 6 - 13 en una cantidad eficaz.
ARP210103609A 2020-12-21 2021-12-21 VACUNA BASADA EN AAV5 PARA LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL SARS-CoV-2 Y/O LA PREVENCIÓN DE LA INFECCIÓN POR CORONAVIRUS RELACIONADA CON EL SARS-CoV-2 AR124461A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2020142220A RU2760301C1 (ru) 2020-12-21 2020-12-21 Вакцина на основе AAV5 для индукции специфического иммунитета к вирусу SARS-CoV-2 и/или профилактики коронавирусной инфекции, вызванной SARS-CoV-2

Publications (1)

Publication Number Publication Date
AR124461A1 true AR124461A1 (es) 2023-03-29

Family

ID=78719331

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103609A AR124461A1 (es) 2020-12-21 2021-12-21 VACUNA BASADA EN AAV5 PARA LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL SARS-CoV-2 Y/O LA PREVENCIÓN DE LA INFECCIÓN POR CORONAVIRUS RELACIONADA CON EL SARS-CoV-2

Country Status (4)

Country Link
AR (1) AR124461A1 (es)
RU (1) RU2760301C1 (es)
UY (1) UY39582A (es)
WO (1) WO2022139631A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR129552A1 (es) * 2022-06-10 2024-09-04 Joint Stock Company “Biocad” Ácido nucleico con actividad promotora y uso del mismo
WO2024149210A1 (zh) * 2023-01-09 2024-07-18 广东克冠达医药科技有限公司 腺相关病毒衣壳蛋白衍生多肽及其用途
CN117511968B (zh) * 2023-11-06 2024-07-05 军事科学院军事医学研究院军事兽医研究所 表达SARS-CoV-2的S、E和M蛋白的重组金丝雀痘病毒及其构建方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112023035A (zh) * 2020-04-07 2020-12-04 中国医学科学院医学生物学研究所 一种以SARS-CoV-2病毒S蛋白RBD区为抗原的纳米疫苗及其制备
RU2723008C9 (ru) * 2020-05-19 2021-02-09 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Способ получения штамма клеток яичника китайского хомячка, продуцента рекомбинантного белка RBD вируса SARS-CoV-2, штамм клеток яичника китайского хомячка, продуцент рекомбинантного белка RBD вируса SARS-CoV-2, способ получения рекомбинантного белка RBD вируса SARS-CoV-2, тест-система для иммуноферментного анализа сыворотки или плазмы крови человека и ее применение
CN111560354B (zh) * 2020-05-22 2022-07-19 中国人民解放军总医院第五医学中心 重组新型冠状病毒及其制备方法和应用
RU2733832C1 (ru) * 2020-07-28 2020-10-07 Федеральное бюджетное учреждение науки "Государственный научный центр вирусологии и биотехнологии "Вектор" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека (ФБУН ГНЦ ВБ "Вектор" Роспотребнадзора) Искусственный ген Stbl_RBD_TrM_SC2, кодирующий бицистронную структуру, образованную последовательностями рецепторсвязывающего домена гликопротеина S коронавируса SARS-CoV-2, трансмембранного региона, P2A-пептида и гликопротеина G VSV, рекомбинантная плазмида pStem-rVSV-Stbl_RBD_TrM_SC2, обеспечивающая экспрессию искусственного гена, и рекомбинантный штамм вируса везикулярного стоматита rVSV-Stbl_RBD_TrM_SC2, используемый для создания вакцины против коронавируса SARS-CoV-2

Also Published As

Publication number Publication date
RU2760301C1 (ru) 2021-11-23
UY39582A (es) 2022-05-31
WO2022139631A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
AR124461A1 (es) VACUNA BASADA EN AAV5 PARA LA INDUCCIÓN DE INMUNIDAD ESPECÍFICA CONTRA EL SARS-CoV-2 Y/O LA PREVENCIÓN DE LA INFECCIÓN POR CORONAVIRUS RELACIONADA CON EL SARS-CoV-2
Heaton et al. In vivo bioluminescent imaging of influenza a virus infection and characterization of novel cross-protective monoclonal antibodies
CO6290791A2 (es) Vacunas y composiciones inmunogénicas que contienen nuevas cepas del circo virus porcino tipo 2b para inmunizar cerdos contra pmws
Gao et al. Twenty amino acids at the C-terminus of PA-X are associated with increased influenza A virus replication and pathogenicity
ZA202301438B (en) Aa v5-based vaccine against sars-cov-2
Wagner et al. N-Glycans attached to the stem domain of haemagglutinin efficiently regulate influenza A virus replication
Noah et al. Influenza virus virulence and its molecular determinants
Nogales et al. Functional Characterization and Direct Comparison of Influenza A, B, C, and D NS1 Proteins in vitro and in vivo
BR112022022604A2 (pt) Vírus recombinante da doença de newcastle expressando proteína spike sars-cov-2 e seus usos
AR083839A1 (es) Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos
Zhang et al. Enhanced pathogenicity and neurotropism of mouse-adapted H10N7 influenza virus are mediated by novel PB2 and NA mutations
Yao-Chen et al. Construction of influenza virus siRNA expression vectors and their inhibitory effects on multiplication of influenza virus
ECSP22021725A (es) Prote?na VP1 modificada aislada de la c?pside del virus adeno-asociado de serotipo 5 (AAV5), c?pside y vector basado en la misma.
Adams et al. The effect of avian influenza virus NS1 allele on virus replication and innate gene expression in avian cells
CO2021011040A2 (es) Virus adenoasociado recombinante para el tratamiento de la neurodegeneración de inicio en adultos asociada a grn
PE20230171A1 (es) Vacunas contra el coronavirus y metodos de uso
Park et al. Effects of HA and NA glycosylation pattern changes on the transmission of avian influenza A (H7N9) virus in guinea pigs
ECSP23056133A (es) Efecto sinérgico de smn1 y mir-23a en el tratamiento de la atrofia muscular espinal
Gubareva et al. A release-competent influenza A virus mutant lacking the coding capacity for the neuraminidase active site
Kuznetsova et al. Adaptive mutation in nuclear export protein allows stable transgene expression in a chimaeric influenza A virus vector
Chung et al. A variant NS1 protein from H5N2 avian influenza virus suppresses PKR activation and promotes replication and virulence in mammals
Avanthay et al. NS1 and PA-X of H1N1/09 influenza virus act in a concerted manner to manipulate the innate immune response of porcine respiratory epithelial cells
Wang et al. Emergence and evolution of the 1918, 1957, 1968, and 2009 pandemic virus strains
Martinez-Sobrido et al. AGL2017-82570-RReverse genetics approaches for the development of new vaccines against influenza A virus infections
Su et al. Emergence and pandemic potential of avian influenza a (H7N9) virus